Arrowhead’s brain shuttle milestone reported first human target-engagement data supporting systemic central nervous system delivery of an siRNA program targeting tau. Company disclosures indicate that the early evidence supports delivery to the intended site in the brain, but the balance between sufficient and excessive tau knockdown remains unresolved. The milestone is particularly relevant given ongoing clinical uncertainty around whether degree and timing of tau lowering translate into efficacy without unacceptable safety trade-offs. Arrowhead’s framing suggests that dose selection—how much tau silencing is “enough” versus “too much”—will be a central theme as programs progress. For the industry, the update strengthens the case for CNS delivery platforms but also reinforces that target engagement is only the first step; dosing strategy is where late-stage risk concentrates.